Shots:

• The approval is based on P-III Archway study evaluates Susvimo (100 mg/mL- IV- q3mos.) via ocular implant vs ranibizumab (0.5mg- IV) in 415 patients with wet AMD prior responded to 2 anti- VEGF
• The results showed that the therapy achieved & maintained vision gains equivalent to ranibizumab @ 36 & 40wks.; 1.6% of patients received supplemental ranibizumab treatment & 98% can go 6mos. before 1st refill. The therapy was well-tolerated with a favorable benefit-risk profile
• Susvimo is expected to be available in the US in the coming mos. & is also currently under EMA’s review for wet AMD. The company plans to provide patient assistance programs through Genentech access solutions

 ­ | Ref: Genentech | Image: Center for Health Journalism